Publications

Merz, M., Gagelmann, N., Smaili, S., Flossdorf, S., Sauer, S., Scheid, C., von Tresckow, B., Wulf, G. G., Weisel, K. C., Blau, I., Engelhardt, M., Wäsch, R., Schub, N., Teipel, R., Hecker, J. S., Waldschmidt, J. M., Besemer, B., Baermann, B. N., Call, S., Hansmann, L., … Kröger, N. (2025). Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST. Blood, blood.2025028330. Advance online publication. https://doi.org/10.1182/blood.2025028330

Braun, T., Kuschel, F., Reiche, K., Merz, M., & Herling, M. (2025). Emerging T-cell lymphomas after CAR T-cell therapy. Leukemia, 39(6), 1337–1341. https://doi.org/10.1038/s41375-025-02574-x

Ferle, M., Grieb, N., Kreuz, M., Ader, J., Goldschmidt, H., Mai, E. K., Bertsch, U., Platzbecker, U., Neumuth, T., Reiche, K., Oeser, A., & Merz, M. (2025). Predicting progression events in multiple myeloma from routine blood work. NPJ digital medicine, 8(1), 231. https://doi.org/10.1038/s41746-025-01636-9

Braun, T., Rade, M., Merz, M., Klepzig, H., Große, F., Fandrei, D., Pham, N. N., Kreuz, M., Kuhn, C. K., Kuschel, F., Löffler, D., Meinel, J., Heger, E., Schweinsberg, V., Pflug, N., Platzbecker, U., Hallek, M., Holtick, U., Köhl, U., Scheid, C., … Richardson, T. (2025). Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody. Nature medicine, 31(4), 1145–1153. https://doi.org/10.1038/s41591-025-03499-9

Fandrei, D., Seiffert, S., Rade, M., Rieprecht, S., Gagelmann, N., Born, P., Wiemers, T., Weidner, H., Kreuz, M., Schassberger, T., Koßmann, J., Mangold, M., Fürst, D., Fischer, L., Baber, R., Heyn, S., Wang, S. Y., Bach, E., Hoffmann, S., Metzeler, K. H., … Merz, M. (2025). Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma. Blood cancer discovery, 6(1), 38–54. https://doi.org/10.1158/2643-3230.BCD-24-0118